Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lispro (Humalog) Clear all
Completed Phase 2Phase 3 Interventional Results available

The Insulin-Only Bionic Pancreas Bridging Study

NCT03565666
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog, iLet Bionic Pancreas insulin-only configuration with Fiasp, Usual care
Device · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 24, 2026, 6:42 AM EDT
Terminated Phase 4 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®

NCT00356421
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled Human Insulin (Exubera®), Insulin lispro (Humalog)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2009 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

NCT03214380
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
933 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Fresno, California • La Mesa, California • Lancaster, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 24, 2026, 6:42 AM EDT
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 2 Interventional

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

NCT01000922
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Regular Human Insulin, Lispro, VIAject, VIAject 50%, VIAject/Insulin Glargine, Insulin Glargine/VIAject
Drug
Lead sponsor
Biodel
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Results available

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

NCT03662334
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection
Drug · Device
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

NCT05463744
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes
Interventions
Insulin Efsitora Alfa, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Concord, California • Fresno, California • Montclair, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 3 Interventional

Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin

NCT00231725
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
insulin lispro injection [rDNA origin] Low Mix
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
25 Years to 75 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 26, 2007 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin

NCT00036504
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Lispro low mixture
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 79 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
13
States / cities
La Jolla, California • Walnut Creek, California • New Britain, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 24, 2026, 6:42 AM EDT
Withdrawn Phase 3 Interventional

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

NCT04254380
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Gan & Lee Insulin Lispro Injection, Humalog
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anaheim, California • Fresno, California • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 24, 2026, 6:42 AM EDT
Terminated Phase 3 Interventional Results available

Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin

NCT01136746
View directory record Official record
Conditions
Hyperglycemia
Interventions
Human regular insulin, Insulin lispro, Insulin glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Sep 24, 2026, 6:42 AM EDT
Withdrawn Phase 2 Interventional

A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.

NCT01067118
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
LINjeta U-100 Insulin, Humalog U-100
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Stanford, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 24, 2026, 6:42 AM EDT
Terminated Not applicable Interventional

Glucagon Counterregulation in Type 1 Diabetes

NCT03547427
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM, Acetaminophen test, Insulin-induced hypoglycemia, Exercise-induced hypoglycemia
Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 1 Interventional

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

NCT02603510
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR342434, insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 2 Interventional

21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

NCT03156361
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
HDV insulin lispro 100 UNIT/mL, Insulin Lispro 100 Units/mL
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

NCT00976391
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
142
States / cities
Birmingham, Alabama • Dothan, Alabama • Gilbert, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Insulins Aspart and Lispro in Insulin Pumps

NCT00461331
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Aspart, Insulin Lispro
Drug
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Not applicable Interventional Results available

Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling

NCT01684943
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Multiplex pharmacokinetic profiling, Continuous insulin monitoring
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 1 Diabetes Mellitus

NCT01481779
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Glargine, LY2605541, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Concord, California • Escondido, California • Fresno, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 4 Interventional

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

NCT00551538
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lispro mix 75/25, Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Results available

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

NCT01378117
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
Interventions
Sitagliptin, glargine, lispro
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 24, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Results available

A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus

NCT04157738
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes
Interventions
Rapid-Acting Insulin, Long acting insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
7 Years to 15 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Sep 24, 2026, 6:42 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Perioperative Glucose Monitoring and Treatment to Reduce Risk of Surgical Site Infections and Complications

NCT06765655
View directory record Official record
Conditions
Surgical Site Infections, Stress Hyperglycemia
Interventions
Insulin Lispro Injection, glucose testing
Drug · Diagnostic Test
Lead sponsor
St. Peter's Hospital, Albany, NY
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 24, 2026, 6:42 AM EDT
Completed No phase listed Observational Results available

Assessment of Mealtime Bolus Insulin Behavior

NCT03368807
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Escondido, California • Los Angeles, California • Ventura, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 24, 2026, 6:42 AM EDT